Drug firm Aurobindo Pharma Friday said the company, its Director P V Ramprasad Reddy and step-down subsidiary Aurolife Pharma LLC, have been made party to a litigation proceeding in the US.
The drug firm in a regulatory filing however said it is yet to receive a copy of the proceeding and denied what it said were 'baseless allegations' against the company.
"Company, Aurolife Pharma LLC, a step-down wholly owned subsidiary in US and P V Ramprasad Reddy, our Director have been made party to a litigation proceeding in the United States of America," Aurobindo Pharma said in a filing to BSE.
The company was reacting to a media report as per which, bankrupt US drug firm Aceto Corporation has accused Aurobindo Pharma and its founder P V Ramprasad Reddy of sabotage and has sought damages in a case filed in the US.
"On preliminary examination of the compliant, the company has been advised by its legal advisors that the case appears to be devoid of merits and consists of baseless allegations against the company, Aurolife and P V Ramprasad Reddy alleging fraud, negligent misrepresentation and the failure of the company and Aurolife to fulfill their obligations, inter-alia, under a supply contract entered into with the company", Aurobindo Pharma said.
In a filing on BSE, the company said: "We deny all the contentions and allegations set out and alluded to in the media report."
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
